It is well known that for treatment of advanced NSCLC, epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) and chemotherapy is recommended as first-line therapy for patients with active EGFR mutation and wild type EGFR, respectively. Here, EGFR is linked to non-small cell lung carcinoma.